Efficacy of Lianhua Qingwen for children with SARS-CoV-2 Omicron infection: A propensity score-matched retrospective cohort study

[1]  Ji Ma,et al.  Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children’s medical center in Shanghai, China , 2022, World Journal of Pediatrics.

[2]  Dandan Tian,et al.  The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection , 2022, Vaccines.

[3]  J. Zahradník,et al.  Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.

[4]  Zhonglin Wang,et al.  Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China , 2022, Journal of Infection.

[5]  Lei Huang.  Adjusted control rate closely associated with the epidemiologic evolution of the recent COVID-19 wave in Shanghai, with 94.3% of all new cases being asymptomatic on first diagnosis , 2022, Journal of Infection.

[6]  Yingxia Liu,et al.  Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children , 2022, Signal Transduction and Targeted Therapy.

[7]  Ting-Yan Zhang,et al.  Pediatric patients in the new wave of SARS-CoV-2 infection in Shanghai, China , 2022, World Journal of Pediatrics.

[8]  I. Shavit,et al.  Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel. , 2022, JAMA.

[9]  Wenhong Zhang,et al.  Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic , 2022, The Lancet.

[10]  L. Abu-Raddad,et al.  COVID-19 Disease Severity in Children Infected with the Omicron Variant , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Frank Zhu,et al.  COVID-19 Infection in Children: Diagnosis and Management , 2022, Current Infectious Disease Reports.

[12]  Gheyath K Nasrallah,et al.  Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.

[13]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[14]  I. Heyman,et al.  Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study , 2022, The Lancet Child & Adolescent Health.

[15]  K. Telle,et al.  Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study , 2022, BMJ.

[16]  P. Maes,et al.  Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern , 2021, bioRxiv.

[17]  Mingshe Zhu,et al.  Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening , 2020, Acta Pharmaceutica Sinica B.

[18]  S. Aljunid,et al.  Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis , 2020, Scientific Reports.

[19]  W. Guan,et al.  Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial , 2020, Phytomedicine.

[20]  Li Xiaobo,et al.  Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) , 2020, Pharmacological Research.

[21]  Zi-feng Yang,et al.  The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function , 2017, BMC Complementary and Alternative Medicine.

[22]  E. Matheson,et al.  Diagnosis, Treatment, and Prevention , 2014 .